No Data
No Data
There is a risk of diffusion! WHO has launched a global strategic preparedness, and monkeypox concept stocks have surged in response.
New variant appears.
Nanjing Hicin Pharmaceutical: Half-year report for the year 2024.
Nanjing Hicin Pharmaceutical: Summary of Half-Year Report in 2024.
Nanjing Hicin Pharmaceutical (300584.SZ): net income in the first half of the year was 24.7363 million yuan, a year-on-year increase of 27.02%.
Nanjing Hicin Pharmaceutical (300584.SZ) announced that the operating revenue for the reporting period was 0.237 billion yuan, a decrease of 9.56% year-on-year; the net profit attributable to shareholders of the listed company was 24.7363 million yuan, an increase of 27.02% year-on-year; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.5154 million yuan, an increase of 35.13% year-on-year; the basic earnings per share was 0.2061 yuan.
Optimistic Investors Push Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Shares Up 29% But Growth Is Lacking
Nanjing Hicin Pharmaceutical (300584.SZ): Shareholder Liu Xiaoquan's shareholding period has expired, with a total reduction of 0.7827 million shares.
On August 19th, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) announced that it had previously disclosed the "Pre-disclosure Announcement on Shareholding Reduction of Shareholders Holding Over 5% of the Company's Shares". Mr. Liu Xiaoquan, a shareholder who holds 6,782,608 shares of the company's stock (5.65217% of the total share capital), plans to reduce his shareholding by no more than 1,082,700 shares (0.90225% of the total share capital) through centralized bidding and bulk transaction within three months after 15 trading days from the announcement disclosure. Currently, Mr. Liu Xiaoquan holds 5,999,908 shares of the company, accounting for the total share capital.
No Data